RecruitingPhase 2NCT07721025
Cardiovascular
Hypertrophic Cardiomyopathy
Also known as HCM, HOCM, hypertrophic obstructive cardiomyopathy, MYBPC3/MYH7
Hypertrophic Cardiomyopathy is the most common inherited heart muscle disease, characterised by unexplained left ventricular hypertrophy, myocardial fibre disarray, and increased risk of sudden cardiac death, particularly in young athletes.
ORPHA:217569 ↗Gene MYBPC3Gene MYH7Gene TNNT2Prevalence 1 per 500Onset Any age; often detected in adolescence or young adulthoodAutosomal dominant
74
studies recruiting now
as of 7 Sept 2026
397
studies registered in total
as of 7 Sept 2026
9
countries with a recruiting site
as of 7 Sept 2026
22 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT06409585
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
RecruitingNCT05489705
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
RecruitingNCT07420907
Study of the Progression of Chronic Cardiovascular Conditions
RecruitingNCT06610019
Cardiovascular Multimodality Imaging Study
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 74 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Hypertrophic Cardiomyopathy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: SHaRe Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy is the most common inherited heart muscle disease, characterised by unexplained left ventricular hypertrophy, myocardial fibre disarray, and increased risk of sudden cardiac death, particularly in young athletes. Mutations in genes encoding sarcomeric proteins, most frequently MYBPC3 and MYH7, are identified in approximately 60% of familial cases. Clinical presentation is highly variable, ranging from lifelong asymptomatic hypertrophy to severe heart failure and ventricular arrhythmia, with the outflow tract obstruction variant (HOCM) being amenable to cardiac myosin inhibitor therapy.
Common clinical features
Exertional dyspnoea and reduced exercise toleranceChest pain (angina) on exertionPalpitations and awareness of irregular heartbeatPre-syncope or syncope, particularly with exertionLeft ventricular wall thickness greater than 15mm on echocardiographyDynamic left ventricular outflow tract obstructionMitral regurgitation due to systolic anterior motionIncreased risk of sudden cardiac death in high-risk individuals
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 approved treatment and 21 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Mavacamten (Camzyos)
Phase 3Sotagliflozin (Inpefa)
Phase 3Atorvastatin (Cardyl)
Phase 3Rivaroxaban (Rivaroxaban accord)
Phase 3Aspirin (8-hour bayer)
Phase 3Perhexiline
Phase 3Metoprolol Succinate (Kapspargo sprinkle)
Phase 2/3Valsartan (Diovan)
Phase 2/3Sacubitril (Sacubitril component of entresto)
+ 13 more in development
Before you apply
Things trial teams commonly ask about for Hypertrophic Cardiomyopathy. Not eligibility rules; those are set by each study.
- Genotype status (sarcomere-positive vs. genotype-negative HCM) affects eligibility for some precision trials; ensure comprehensive sarcomere gene panel testing has been performed.
- Resting and provoked left ventricular outflow tract gradient measurements are central eligibility criteria for cardiac myosin inhibitor trials; bring current echocardiography reports.
- History of septal reduction procedures (surgical myectomy or alcohol septal ablation) may exclude participation in some trials; disclose all prior interventions.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).